Lv2
110 积分 2025-04-25 加入
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
22天前
已完结
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
23天前
已完结
Opportunistic Salpingectomy for Prevention of Tubo-Ovarian Carcinoma
25天前
已关闭
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
27天前
已完结
Hallmarks of cancer-Then and now, and beyond
1个月前
已完结
State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025
3个月前
已完结
Cholesterol desensitizes the response of endometrial cancer to progestin by attenuating progestin signaling
3个月前
已完结
Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: a systematic review and meta-analysis
3个月前
已完结
Ovarian Cancer
3个月前
已完结
Gauging the Magnitude of Missed Opportunity for Ovarian Cancer Prevention
3个月前
已完结
皖公网安备34019202002308
